Physicians and patients alike have often wondered if these therapies are bad for the heart. It turns out, according to this new analysis, that they can be quite beneficial. 

The sensors of certain FreeStyle Libre 3 devices are producing inaccurate glucose readings and should not be used. Two patient injuries have been reported. Abbott first reported the problem in July. 

The findings, based on data from more than 800 TAVR patients, suggest that skipping OAC medications for a small amount of time could make a big impact.

Cardio-rheumatology clinics use a heart team-like approach to enhance care for patients with chronic conditions such as lupus, psoriasis and rheumatoid arthritis. "It's not just about cardiology," the director of one clinic explains. "We work closely with rheumatologists, dermatologists and even primary care physicians to provide comprehensive care."

Should patients stay on beta-blockers more than one year after a heart attack? The team behind the ABYSS clinical trial explored that very question, presenting its data at ESC Congress 2024.

Insulet's Omnipod 5 Automated Insulin Delivery System was already cleared to help patients manage type 1 diabetes. 

The Cardiovascular Research Foundation has announced 10 late-breaking clinical trials and 15 late-breaking clinical science sessions for TCT 2024 in Washington, DC. Topics will include TAVR and other structural heart procedures, artificial intelligence and much more. 

Medications that target obesity are not typically covered by Medicare. When the FDA approved semaglutide as a way to treat certain cardiovascular risks, however, CMS said Medicare coverage was on the table.